n
usa
western
nation
respiratori
syncyti
viru
one
commonli
encount
respiratori
virus
among
patient
diagnos
hematolog
malign
undergon
stem
cell
transplant
multipl
studi
perform
evalu
complic
associ
respiratori
syncyti
viru
infect
studi
evalu
therapeut
agent
strategi
agent
use
also
numer
report
outbreak
bone
marrow
transplant
unit
oncolog
ward
infect
control
measur
invalu
control
spread
diseas
howev
despit
novel
approach
respiratori
syncyti
viru
continu
potenti
fatal
immunocompromis
popul
review
discuss
incid
respiratori
syncyti
viral
infect
risk
factor
associ
progress
upper
respiratori
tract
infect
lower
respiratori
tract
infect
complic
outcom
includ
mortal
manag
strategi
prevent
strategi
patient
hematolog
malign
hematopoiet
cell
transplant
recipi
commun
respiratori
virus
common
caus
respiratori
infect
virus
perhap
best
known
season
variat
outcom
infect
vari
basi
patient
popul
advers
outcom
describ
hematopoiet
cell
transplant
hct
recipi
patient
hematolog
malign
hm
one
common
commun
respiratori
virus
may
lead
death
hct
recipi
hm
patient
respiratori
syncyti
viru
rsv
whose
incid
second
influenza
accord
prior
report
virus
includ
parainfluenza
viru
metapneumoviru
adenoviru
rhinoviru
bocaviru
differ
strategi
use
manag
rsv
infect
immunocompromis
patient
hct
recipi
particular
includ
ribavirin
differ
formul
intraven
immunoglobulin
ivig
rsv
immunoglobulin
rsv
monoclon
antibodi
addit
effect
measur
use
curtail
outbreak
rsv
infect
numer
bone
marrow
transplant
unit
oncolog
ward
success
howev
despit
advanc
past
two
decad
earli
detect
manag
rsv
infect
immunocompromis
patient
outcom
relat
infect
remain
poor
review
summar
publish
data
rsv
infect
adult
hct
recipi
hm
patient
focus
recent
find
highlight
incid
rsv
infect
risk
factor
associ
progress
upper
respiratori
tract
infect
urti
lower
respiratori
tract
infect
lrti
complic
outcom
includ
mortal
manag
strategi
includ
new
agent
investig
prevent
strategi
respiratori
viral
infect
popul
approxim
infect
result
lrti
determin
true
incid
rsv
infect
among
hct
recipi
challeng
report
wide
rang
mani
studi
includ
symptomat
patient
diagnos
differ
laboratori
assay
rsv
antigen
detect
identif
rsv
direct
floresc
antibodi
viral
cultur
molecular
assay
recent
year
tabl
addit
wide
rang
report
incid
rsv
infect
could
due
increas
awar
viru
year
impact
immunocompromis
patient
hand
lower
incid
rsv
infect
report
studi
molecular
assay
multiplex
polymeras
chain
reaction
use
detect
rsv
report
rang
case
lower
incid
could
explain
increas
rate
diagnos
respiratori
virus
coronaviru
rhinoviru
parainfluenza
use
molecular
assay
proport
rsv
infect
caus
lrti
hct
recipi
rang
higher
rate
report
earlier
year
earli
wherea
recent
studi
sinc
year
lower
rate
lrti
observ
could
possibl
explain
increas
use
ribavirin
earlier
stage
rsv
infect
prevent
infect
progress
lower
respiratori
tract
well
use
molecular
assay
detect
rsv
also
respiratori
virus
recent
studi
fred
hutchinson
cancer
research
center
respiratori
viral
infect
hct
patient
appli
specif
definit
better
delin
type
lrti
associ
respiratori
viral
infect
patient
proven
probabl
lrti
defin
patient
microbiolog
detect
respiratori
virus
lower
respiratori
tract
without
radiolog
evid
diseas
lung
respect
patient
possibl
lrti
defin
patient
microbiolog
detect
respiratori
virus
upper
respiratori
tract
radiolog
evid
diseas
lung
one
studi
proport
patient
provenprob
possibl
rsv
lrti
respect
interestingli
author
show
patient
proven
probabl
lrti
higher
need
supplement
oxygen
use
mechan
ventil
compar
possibl
lrti
definit
also
appli
studi
coronaviru
parainfluenza
viru
rhinoviru
data
rsv
infect
hm
patient
scarc
studi
report
rate
rsv
infect
patient
earli
studi
incid
rsv
among
symptomat
hm
patient
includ
hct
recipi
larg
proport
infect
diagnos
lrti
similar
studi
report
rang
sampl
size
rel
ly
small
recent
studi
hm
patient
rsv
infect
identifi
year
present
urti
lrti
respect
among
hm
patient
urti
progress
develop
lrti
patient
leukemia
multipl
myeloma
none
lymphoma
recent
studi
institut
focus
rsv
lrti
hm
patient
undergon
hct
found
hm
patient
undergon
hct
defin
possibl
rsv
lrti
bronchoscopi
perform
patient
time
diagnosi
data
avail
regard
rsv
infect
pediatr
hct
recipi
estim
incid
rsv
infect
among
popul
develop
lrti
signific
complic
rsv
infect
hm
patient
hct
recipi
progress
lrti
associ
higher
mortal
rate
mani
risk
factor
progress
identifi
hope
target
popul
could
benefit
earli
therapi
could
identifi
risk
factor
primarili
consist
host
factor
previou
studi
rsv
serotyp
b
found
differ
outcom
assist
identif
hct
recipi
risk
progress
lrti
fatal
outcom
immunodefici
score
index
isi
rsv
develop
base
combin
multipl
host
risk
factor
mean
applic
respiratori
virus
six
factor
includ
score
index
neutropenia
less
neutrophilsml
lymphopenia
less
lymphocytesml
age
greater
year
graftversushost
diseas
steroid
use
myeloabl
chemotherapi
time
hct
basi
total
score
isi
stratifi
hct
recipi
rsv
urti
lowrisk
score
mediumrisk
score
highrisk
score
categori
risk
factor
identifi
studi
includ
isi
smoke
statu
hypoxia
nosocomi
infect
match
unrel
donormismatch
donor
statu
prior
autolog
hct
stem
cell
sourc
tabl
isi
rsv
valid
author
tabl
wang
et
al
found
allogen
hct
recipi
high
isi
score
experienc
progress
pneumonia
diagnos
rsv
influenza
coronaviru
adenoviru
current
predict
score
index
progress
respiratori
virus
patient
leukemia
lymphoma
multipl
myeloma
hand
welldescrib
risk
factor
associ
progress
lrti
hm
patient
includ
lymphopenia
neutropenia
gener
defin
lymphocytesml
neutrophilsml
respect
multipl
retrospect
analys
hct
recipi
lymphocytopenia
neutropenia
time
diagnosi
rsv
independ
predictor
progress
lrti
cohort
allogen
hct
recipi
rsv
infect
hazard
ratio
hr
experienc
progress
rsv
urti
lrti
absolut
neutrophil
count
cellsml
absolut
lymphocyt
count
cellsml
make
predict
factor
progress
among
leukemia
patient
postinduct
chemotherapi
neutropenia
leukopenia
also
shown
increas
risk
progress
lrti
recent
retrospect
studi
neutropenia
lymphopenia
independ
associ
progress
diseas
hm
patient
combin
two
factor
associ
higher
risk
progress
howev
time
last
chemotherapi
shown
play
role
progress
lrti
hm
patient
hand
lack
ribavirin
therapi
associ
progress
dishaematologica
protect
benefit
ribavirin
discuss
treatment
section
certain
longterm
complic
rsv
infect
describ
hct
recipi
wide
describ
longterm
complic
reduct
pulmonari
function
delay
engraft
rsv
infect
less
commonli
describ
uncertain
associ
small
number
patient
decreas
forc
expir
second
fev
baselin
hct
associ
poor
outcom
fact
previou
studi
shown
decreas
fev
greater
associ
develop
bronchiol
obliteran
howev
relationship
respiratori
virus
rsv
particular
chang
fev
marker
pulmonari
function
fulli
understood
limit
data
hct
recipi
pulmonari
function
includ
chang
fev
oxygen
diffus
capac
rsv
infect
avetisyan
et
al
show
compar
control
group
hct
recipi
rsv
infect
like
develop
mild
mark
chang
vital
capac
diffus
capac
pulmonari
function
test
subsequ
seo
et
al
describ
signific
decreas
patient
diffus
capac
month
rsv
infect
persist
year
indic
fev
total
lung
capac
also
affect
sampl
size
small
draw
definit
conclus
anoth
studi
compar
effect
differ
virus
pulmonari
function
hct
recipi
rsv
parainfluenza
associ
fev
decreas
least
postul
subclin
shed
virus
may
augment
airway
inflamm
lead
airway
restrict
comparison
lung
transplant
recipi
infect
respiratori
virus
increas
risk
develop
bronchiol
obliteran
associ
mortal
similarli
hct
recipi
prior
respiratori
viral
infect
like
develop
bronchiol
obliteran
chang
fev
higher
mortal
rate
patient
without
bronchiol
obliteran
hr
delay
fail
engraft
stem
cell
acut
rsv
infect
report
howev
uncommon
complic
total
seven
patient
describ
case
seri
associ
first
describ
mccarthi
et
al
note
four
patient
graft
failur
rsv
infect
preengraft
period
identifi
infect
furthermor
rsv
outbreak
hematolog
unit
australia
delay
neutrophil
platelet
engraft
occur
two
autolog
hct
recipi
graft
failur
occur
one
allogen
hct
recipi
rsv
infect
hand
studi
waghmar
et
al
show
signific
chang
lymphocyt
count
dynam
hct
recipi
experienc
progress
rsv
lrti
compar
patient
overal
limit
data
support
rsv
infect
per
se
lead
graft
failur
contribut
delay
engraft
high
mortal
rate
report
hm
patient
hct
recipi
rsv
infect
rsvattribut
mortal
rate
hct
recipi
vari
outbreak
situat
patient
receiv
reducedintens
condit
regimen
circumst
hct
recipi
develop
rsv
lrti
mortal
rate
rang
note
hct
recipi
rsv
infect
classifi
possibl
rsv
lrti
radiolog
evid
chest
abnorm
neg
bronchoscopi
data
proven
rsv
lrti
rsv
detect
lower
respiratori
tract
mortal
rate
increas
respect
multipl
risk
factor
mortal
rsv
identifi
hostrel
includ
neutropenia
lymphopenia
time
transplant
infect
cell
sourc
older
age
steroid
exposur
graftversushost
diseas
hypoxia
use
myeloabl
chemotherapi
rsvisi
valid
predict
mortal
risk
hct
recipi
tabl
base
deriv
cohort
allogen
hct
recipi
rsv
infect
predict
mortal
patient
high
rsvisi
one
valid
cohort
interestingli
studi
show
ribavirin
may
protect
effect
hct
recipi
hm
patient
discuss
treatment
section
delay
transplant
patient
diagnos
rsv
respiratori
virus
prior
hct
shown
improv
surviv
campbel
et
al
review
patient
pretranspl
respiratori
viral
infect
found
regardless
viru
higher
mortal
rate
without
infect
institut
hct
delay
approxim
week
patient
diagnos
rsv
infect
prior
transplant
among
hct
recipi
rsv
infect
mortal
consider
lower
pediatr
patient
adult
mortal
vari
among
pediatr
hct
recipi
rsv
infect
higher
patient
lrti
mortal
rate
amongst
hm
patient
rsv
high
mortal
rate
small
studi
conduct
among
leukemia
patient
rsv
lrti
recent
undergon
myelosuppress
chemotherapi
recent
studi
hm
patient
rsv
lrti
found
mortal
rate
better
outlook
could
explain
part
improv
support
care
year
use
ribavirin
treatment
rsv
popul
patient
risk
factor
associ
mortal
rsvinfect
leukemia
patient
includ
neutropenia
neutrophilsml
lymphopenia
lymphocytesml
high
apach
ii
score
diagnosi
host
factor
reflect
patient
immun
statu
abil
curtail
impact
rsv
infect
sever
stage
infect
urti
vs
lrti
virul
rsv
may
also
affect
mortal
hm
patient
proven
lrti
mortal
rate
report
compar
patient
possibl
lrti
recent
retrospect
analysi
patient
hm
includ
hct
recipi
respiratori
viral
infect
detect
intens
care
unit
higher
intens
care
unit
mortal
rate
associ
strongest
influenza
parainfluenza
rsv
detect
current
treatment
rsv
infect
immunocompromis
adult
patient
ribavirin
differ
formul
although
approv
food
drug
administr
fda
purpos
immunomodul
convent
ivig
rsv
monoclon
antibodi
palivizumab
ribavirin
nucleosid
analog
activ
broad
spectrum
rna
virus
act
intercal
rna
viru
enhanc
mutat
rate
ribavirin
avail
aerosol
oral
intraven
formul
aerosol
ribavirin
approv
fda
treatment
rsv
lrti
hospit
infant
young
children
studi
formul
hct
recipi
convent
dose
regimen
g
deliv
h
small
particl
aerosol
gener
patient
scaveng
tent
decreas
environment
contamin
exposur
healthcar
worker
ribavirin
teratogen
altern
regimen
total
dose
ribavirin
given
divid
three
dose
per
day
g
h
time
day
intermitt
regimen
shown
equival
convent
continu
regimen
adapt
random
trial
studi
use
ribavirin
rsv
infect
hct
recipi
hm
patient
retrospect
natur
lack
comparison
control
group
yet
cumul
evid
albeit
clinic
trial
suggest
better
outcom
ribavirin
use
hct
recipi
earli
diseas
urti
decreas
rate
progress
rsv
urti
lrti
aerosol
ribavirin
therapi
hct
recipi
rsv
infect
pronounc
one
studi
random
control
trial
halt
complet
enrol
differ
reason
includ
slow
accrual
show
trend
toward
lower
rate
progress
lrti
aerosol
ribavirin
use
nine
patient
treat
ribavirin
one
experienc
progress
compar
two
five
patient
treat
system
review
treatment
rsv
infect
adult
hct
recipi
show
overal
reduct
rate
progress
lrti
reduct
rate
rsvrelat
mortal
patient
lrti
earli
treatment
aerosol
ribavirin
largest
retrospect
studi
date
impact
aerosol
ribavirin
therapi
hct
recipi
rsv
infect
earli
ribavirin
therapi
urti
stage
reduc
risk
progress
lrti
addit
lack
ribavirin
therapi
associ
increas
mortal
rate
odd
ratio
data
use
ribavirin
hm
patient
rsv
infect
limit
sever
retrospect
studi
demonstr
earli
use
aerosol
ribavirin
reduc
mortal
rate
leukemia
patient
rsv
infect
larg
retrospect
studi
hm
patient
show
better
outcom
aerosol
ribavirin
hand
vakil
et
al
found
ribavirin
use
either
urti
lrti
stage
reduc
overal
mortal
object
studi
assess
risk
factor
mortal
role
ribavirin
hm
patient
although
studi
show
posit
trend
toward
benefit
therapi
ribavirin
specif
recommend
made
present
despit
experi
aerosol
ribavirin
treatment
rsv
infect
adult
hct
recipi
increas
popular
year
major
shift
oral
formul
occur
around
year
ago
least
institut
cost
ribavirin
increas
drastic
oral
ribavirin
use
treat
rsv
urti
lrti
hct
recipi
hm
patient
dose
regimen
vari
weightbas
regimen
mgkg
mgkg
standard
dosag
mg
twice
daili
mg
three
time
daili
maximum
mgday
oral
ribavirin
readili
avail
aerosol
ribavirin
well
toler
basi
data
longterm
use
patient
hepat
c
viru
infect
retrospect
analysi
experi
aerosol
ribavirin
recent
switch
oral
ribavirin
found
signific
differ
outcom
includ
progress
lrti
day
allcaus
mortal
hct
recipi
rsv
infect
basi
result
recent
analysi
propos
use
oral
ribavirin
viabl
altern
aerosol
ribavirin
figur
institut
implement
decisionmak
treatment
algorithm
guidanc
clinic
provid
hct
recipi
stratifi
basi
rsvisi
score
stage
rsv
diagnosi
urti
vs
lrti
side
effect
associ
oral
aerosol
ribavirin
report
prior
public
one
common
side
effect
associ
aerosol
ribavirin
patient
often
complain
feel
lone
see
hail
scaveng
tent
report
hepatotox
associ
use
aerosol
ribavirin
random
placebocontrol
trial
assess
use
aerosol
ribavirin
treatment
rsv
hct
recipi
rate
hepatotox
similar
two
group
although
sampl
size
small
side
effect
note
trial
hepatotox
report
associ
use
oral
ribavirin
treatment
hepat
c
viru
howev
observ
hepatotox
probabl
due
coadministr
interferon
therapi
retrospect
studi
assess
use
oral
ribavirin
immunocompromis
patient
includ
hct
recipi
one
patient
receiv
oral
ribavirin
develop
hemolyt
anemia
lactic
acidosi
latter
thought
due
sever
gastrointestin
graftversushost
diseas
recent
retrospect
analysi
compar
outcom
hct
recipi
rsv
infect
receiv
either
aerosol
oral
ribavirin
two
patient
oral
ribavirin
develop
newonset
grade
anemia
day
compar
two
patient
receiv
aerosol
formul
studi
demonstr
aerosol
oral
ribavirin
similar
safeti
profil
intraven
ribavirin
use
treat
rsv
infect
hct
recipi
common
regimen
use
singl
mgkg
load
dose
follow
mgkg
four
time
day
day
mainten
dose
mgkg
three
time
day
symptom
resolv
intraven
formul
ribavirin
readili
avail
usa
due
lack
fda
approv
howev
acquir
fda
emerg
compassion
use
mani
immunomodul
use
adjunct
therapi
rsv
infect
adult
hm
patient
hct
recipi
random
control
trial
compar
benefit
ad
ivig
ribavirin
therapi
mani
retrospect
analys
report
variabl
result
combin
shah
et
al
suggest
minim
benefit
hct
recipi
rsv
infect
hct
patient
treat
combin
therapi
surviv
one
patient
treat
ribavirin
alon
die
evalu
multivari
analysi
anoth
studi
show
clinic
benefit
hct
recipi
receiv
weekli
highdos
ivig
adjunct
therapi
rsv
infect
hypothes
human
ivig
lack
suffici
specif
antibodi
rsv
would
explain
mix
result
seen
retrospect
studi
rsvspecif
monoclon
antibodi
palivizumab
also
evalu
treatment
rsv
infect
hct
recipi
hm
patient
origin
palivizumab
approv
prevent
rsv
infect
neonat
children
experi
palivizumab
treatment
hct
recipi
rsv
limit
sever
studi
show
surviv
benefit
compar
palivizumab
adjunct
therapi
ribavirin
monotherapi
rsv
infect
adult
hct
recipi
recent
retrospect
studi
mix
popul
adult
hct
recipi
patient
hm
treat
palivizumab
rsv
infect
show
trend
toward
better
surviv
compar
control
group
mortal
rate
compar
respect
howev
differ
statist
signific
recommend
routin
use
palivizumab
popul
patient
made
previous
discuss
limit
therapeut
option
rsv
infect
new
therapi
desper
need
presatovir
oral
rsv
fusion
inhibitor
select
antirsv
activ
vitro
phase
firstinhuman
singleand
multipleascend
dose
studi
presatovir
excel
safeti
profil
despit
extend
halflif
oral
bioavail
also
good
regardless
prandial
state
although
clinic
trial
rsv
infect
transplant
recipi
challeng
due
low
recruit
two
phase
ii
trial
presatovir
hct
recipi
rsv
infect
recent
complet
clinicaltrialsgov
number
overcom
potenti
low
recruit
hct
recipi
rsv
infect
limit
upper
respiratori
tract
recruit
total
center
nine
countri
year
preliminari
data
show
presatovir
effect
reduc
nasal
rsv
viral
load
time
reduc
incid
lower
respiratori
tract
complic
howev
exploratori
analysi
presatovir
reduc
rate
progress
lower
respiratori
tract
complic
patient
lymphopenia
rel
rate
placebotr
patient
furthermor
presatovir
effect
reduc
nasal
rsv
viral
load
supplement
oxygen
use
allcaus
mortal
anoth
phase
ii
trial
hct
recipi
rsv
lrti
sever
lesson
learn
two
trial
hct
recipi
one
risk
factor
ie
lymphopenia
neutropenia
infect
within
year
transplant
poorer
outcom
rsv
infect
may
benefit
effect
antivir
therapi
hand
time
symptom
onset
time
develop
lower
respiratori
tract
complic
probabl
critic
factor
determin
effect
fusion
inhibitor
develop
anoth
novel
agent
recent
stop
drug
may
enter
clinic
trial
rsv
infect
hct
recipi
inhal
agent
trival
nanobodi
inhibit
rsv
replic
bind
fprotein
surfac
viru
therebi
neutral
rsv
block
viru
uptak
cell
recent
phase
trial
infant
rsv
infect
prematur
termin
due
lack
efficaci
clinicaltrialsgov
identifi
prevent
rsv
hm
patient
hct
recipi
limit
infect
control
measur
intervent
mani
report
outbreak
popul
patient
emphasi
multifacet
intervent
includ
complianc
hand
hygien
contact
precaut
gown
use
glove
screen
visitor
healthcar
worker
respiratori
symptom
restrict
visitor
healthcar
worker
symptomat
group
rsvinfect
patient
togeth
sometim
screen
asymptomat
patient
treatment
area
intervent
shown
effect
mix
adult
pediatr
patient
institut
place
patient
diagnos
respiratori
viral
infect
contact
droplet
precaut
interestingli
use
chemoprophylaxi
palivizumab
describ
outbreak
patient
high
risk
acquir
rsv
infect
bone
marrow
transplant
ward
sixteen
asymptomat
patient
given
one
prophylact
dose
palivizumab
outbreak
none
develop
rsv
infect
result
warrant
investig
use
palivizumab
outbreak
howev
definit
recommend
made
time
final
rsv
vaccin
children
adult
avail
present
multipl
trial
children
healthi
adult
progress
www
clinicaltrialsgov
whether
immun
rsv
would
benefici
immunocompromis
patient
uncertain
rsv
common
respiratori
viral
infect
adult
hm
patient
hct
recipi
incid
affect
season
geographi
diagnost
method
use
mortal
rate
associ
rsv
high
sever
immunocompromis
patient
lrti
use
isi
help
stratifi
hct
recipi
risk
categori
similar
score
system
need
hm
patient
ribavirin
without
ivig
may
mitig
impact
rsv
infect
popul
patient
develop
new
antivir
agent
treatment
modal
utmost
import
greater
impact
rate
progress
ltri
mortal
adult
hm
patient
hct
recipi
